Patents Assigned to John B. Davidson
  • Patent number: 5981602
    Abstract: The present invention relates to the use of ajoene for inhibiting integrin-mediated cell-cell fusion. Specific types of cell-cell fusion are giant multinucleated cell formation, syneytia formation, and osteoclast formation.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: November 9, 1999
    Assignee: John B. Davidson
    Inventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
  • Patent number: 5968988
    Abstract: Disclosed herein is the use of ajoene for the treatment of shock.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: October 19, 1999
    Assignee: John B. Davidson
    Inventor: Alexander V. Tatarintsev
  • Patent number: 5948821
    Abstract: The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and antiinflammation effects. In general, Ajoene may be used to treat any integrin-mediated disease or condition.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: September 7, 1999
    Assignee: John B. Davidson
    Inventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
  • Patent number: 5932621
    Abstract: The present invention relates to the use of Ajoene to treat integrin-mediated tumors and metastasis.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: August 3, 1999
    Assignee: John B. Davidson
    Inventor: Alexander V. Tatarintsev
  • Patent number: 5863955
    Abstract: This invention relates to a method of inhibiting an immune response by administering an effective dosage of Ajoene.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: January 26, 1999
    Assignee: John B. Davidson
    Inventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
  • Patent number: 5863954
    Abstract: The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and anti-inflammation effects. In general, Ajoene may be used to treat any integrin-mediated disease or condition.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: January 26, 1999
    Assignee: John B. Davidson
    Inventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
  • Patent number: 5856363
    Abstract: The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and anti-inflammation effects. In general, Ajoene may be used to treat any integrin-mediated disease or condition.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: January 5, 1999
    Assignee: John B. Davidson
    Inventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson